Loading people...
Kristina Burow is a Managing Director at ARCH Venture Partners based in Chicago, Illinois. Since joining the firm as an Associate in 2002, she has specialized in early-stage life sciences investments, following her tenure at the Novartis BioVenture Fund and the Genomics Institute of the Novartis Research Foundation. She has directed or co-founded several prominent biotechnology companies, including Neumora Therapeutics, Scholar Rock, and Beam Therapeutics, contributing to multiple public entities exceeding $1 billion in valuation. Her notable investment track record features leading the early funding for Receptos, which was acquired by Celgene for $7.2 billion. She holds an MBA from the University of Chicago Booth School of Business, alongside chemistry degrees from Columbia University and UC Berkeley. Burow currently focuses on the creation and seed-stage development of pharmaceutical, digital health, deeptech, and artificial intelligence startups.
Kristina Burow stands as a prominent figure in the venture capital landscape, serving as a Managing Director at ARCH Venture Partners. Since joining ARCH in 2002, she has been instrumental in identifying, funding, and building a portfolio of transformative biotechnology companies. Her role extends beyond traditional investing; Burow is deeply involved in the foundational stages of company creation, working closely with scientists and entrepreneurs to translate cutting-edge research into commercial success.
At ARCH Venture Partners, Kristina Burow's investment focus is sharply honed on the life sciences sector, particularly early-stage biotechnology. She seeks out disruptive technologies and scientific breakthroughs that have the potential to address significant unmet medical needs. Her portfolio often includes companies developing novel therapeutics, diagnostics, and medical devices across a wide range of disease areas. Burow's expertise lies in recognizing the commercial viability of nascent scientific discoveries and guiding these ventures through their critical early growth phases.
Kristina Burow's career background provides a strong foundation for her work in biotech venture capital. Prior to her tenure at ARCH, she gained valuable experience as an Associate with the healthcare group of Credit Suisse First Boston, where she honed her financial acumen within the healthcare industry. She holds an MBA from Northwestern University's Kellogg School of Management and a BA from Dartmouth College, demonstrating a robust blend of business strategy and academic rigor. This diverse background allows her to approach investments with both scientific understanding and strategic business insight.
Throughout her career, Burow has been associated with numerous notable investments and has served on the boards of many successful companies. Her involvement has been crucial in the development of firms like Receptos (acquired by Celgene), Unity Biotechnology, Gossamer Bio, Sana Biotechnology, and Beam Therapeutics, among others. These companies represent just a fraction of her impact, showcasing her ability to identify and nurture ventures that go on to make significant contributions to medicine and generate substantial value. Kristina Burow's dedication to fostering innovation continues to shape the future of biotechnology.
Kristina Burow is a Managing Director at ARCH Venture Partners, a leading venture capital firm. She specializes in early-stage biotechnology investments and is deeply involved in the creation and development of new life science companies.
Kristina Burow primarily invests in early-stage biotechnology and life science companies. Her focus areas include novel therapeutics, diagnostics, and medical devices, particularly those translating scientific breakthroughs into commercial products.
Kristina Burow works as a Managing Director at ARCH Venture Partners, a prominent venture capital firm known for its investments in the life sciences and technology sectors.
